These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17604204)

  • 21. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1.
    Pérez-Calvo J; Giraldo P; Pastores GM; Fernández-Galán M; Martín-Nuñez G; Pocoví M
    J Postgrad Med; 2003; 49(2):127-31. PubMed ID: 12867687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE; Aerts JM; Goudsmit R; Phoa SS; Ek M; van Weely S; von dem Borne AE; van Oers MH
    Lancet; 1995 Jun; 345(8963):1474-8. PubMed ID: 7769902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiation treatment with imiglucerase every 3 weeks in type 1 Gaucher disease.
    Serratrice C; Swiader L; Serratrice J; Weiller PJ; Verrot D
    Eur J Intern Med; 2012 Mar; 23(2):e71-2. PubMed ID: 22284262
    [No Abstract]   [Full Text] [Related]  

  • 24. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.
    Weinreb N; Taylor J; Cox T; Yee J; vom Dahl S
    Am J Hematol; 2008 Dec; 83(12):890-5. PubMed ID: 18819093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone density changes with enzyme therapy for Gaucher disease.
    Lebel E; Dweck A; Foldes AJ; Golowa Y; Itzchaki M; Zimran A; Elstein D
    J Bone Miner Metab; 2004; 22(6):597-601. PubMed ID: 15490271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.
    Erikson A; Forsberg H; Nilsson M; Aström M; Månsson JE
    Acta Paediatr; 2006 Mar; 95(3):312-7. PubMed ID: 16497642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase.
    Rosenthal DI; Doppelt SH; Mankin HJ; Dambrosia JM; Xavier RJ; McKusick KA; Rosen BR; Baker J; Niklason LT; Hill SC
    Pediatrics; 1995 Oct; 96(4 Pt 1):629-37. PubMed ID: 7567322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
    J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease.
    Zimran A; Loveday K; Fratazzi C; Elstein D
    Blood Cells Mol Dis; 2007; 39(1):115-8. PubMed ID: 17391996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gaucher disease with pulmonary involvement in a 6-year-old girl: report of resolution of radiographic abnormalities on increasing dose of imiglucerase.
    Lee SY; Mak AW; Huen KF; Lam ST; Chow CB
    J Pediatr; 2001 Dec; 139(6):862-4. PubMed ID: 11743514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy.
    Beutler E
    Blood Cells Mol Dis; 2000 Aug; 26(4):303-6. PubMed ID: 11042031
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.
    Deegan PB; Moran MT; McFarlane I; Schofield JP; Boot RG; Aerts JM; Cox TM
    Blood Cells Mol Dis; 2005; 35(2):259-67. PubMed ID: 16125420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First long-term results of imiglucerase therapy of type 1 Gaucher disease.
    Niederau C; vom Dahl S; Häussinger D
    Eur J Med Res; 1998 Feb; 3(1-2):25-30. PubMed ID: 9512964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
    Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.
    Hollak CE; de Fost M; van Dussen L; Vom Dahl S; Aerts JM
    Expert Opin Pharmacother; 2009 Nov; 10(16):2641-52. PubMed ID: 19743939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzyme augmentation in moderate to life-threatening Gaucher disease.
    Fallet S; Grace ME; Sibille A; Mendelson DS; Shapiro RS; Hermann G; Grabowski GA
    Pediatr Res; 1992 May; 31(5):496-502. PubMed ID: 1603627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC; Chien YH; Lai MY; Hwu WL
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical course of treated and untreated Gaucher disease. A study of 45 patients.
    Beutler E; Demina A; Laubscher K; Garver P; Gelbart T; Balicki D; Vaughan L
    Blood Cells Mol Dis; 1995; 21(2):86-108. PubMed ID: 8846048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
    Grabowski GA; Golembo M; Shaaltiel Y
    Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease.
    Barton NW; Brady RO; Dambrosia JM; Doppelt SH; Hill SC; Holder CA; Mankin HJ; Murray GJ; Zirzow GC; Parker RI
    J Pediatr; 1992 Feb; 120(2 Pt 1):277-80. PubMed ID: 1735829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.